We have moved past the point that we got too last round.
This is normally the last step before approval.
So could we also get news from the FDA in regards to the data filed in the IND ?
That would be a catalist for licensing. Remestemcel-L as a ready to market therapie is worth billions.
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-19
-
- There are more pages in this discussion • 257 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.005(0.42%) |
Mkt cap ! $1.370B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.18 | $2.392M | 2.002M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 16267 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 29315 | 8 |
View Market Depth
| Last trade - 11.27am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |